A Phase 2 Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-Glutathione S-Transferase] Coupled to Oxidized Polymannose) in Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas

Trial Profile

A Phase 2 Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-Glutathione S-Transferase] Coupled to Oxidized Polymannose) in Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Cancer vaccine MUC-1 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Immutep Limited
  • Most Recent Events

    • 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Apr 2015 Status changed from discontinued to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top